Additive Biomanufacturing Platform for Cell‑Laden Hydrogels and Living Constructs (Additive Manufacturing of Cell‑Laden Functional Hydrogel and Live Cell Constructs, Tech ID: 18‑038)
Technology Overview: This technology enables additive manufacturing of hydrogels containing living cells, allowing precise spatial control over biological and structural features of 3D tissue constructs. The platform supports high cell viability while enabling fabrication of complex geometries with embedded functionality. It advances scalable biomanufacturing of tissues for regenerative medicine, drug screening, and disease modeling.
Industry Pain Point: Many bioprinting platforms cannot balance structural fidelity with long‑term cell viability.
NJIT Solution: This approach enables precise, high‑viability bioprinting within functional hydrogel matrices.
Key Features & Advantages
- High post‑printing cell viability
- Precise spatial control of cells and materials
- Scalable and repeatable bioprinting
- Compatible with regenerative applications
Development Stage: TRL 4–5 – Laboratory validation completed.
Target Markets
- Tissue engineering and regenerative medicine
- Bioprinting platforms
- In‑vitro tissue models
Market Opportunity
- Global bioprinting market (2026): ~$2.8B
- CAGR: ~18–20%
- Projected market size (2035): ~$12–14B
Commercial & IP Details
Inventors: Alperen Abaci, Murat Guvendiren, Shen Ji